New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in Children
USA - English
Share this article
Share this article
National Comprehensive Cancer Network publishes first-ever complete medical guidelines for a pediatric solid tumor, so children everywhere receive the best care based on the latest research.
NCCN Guidelines for Wilms Tumor shares information for earlier, safer diagnosis and treatment in effort to reduce disparities; doctors warn of late diagnosis as a possible impact from the COVID-19 pandemic.
PLYMOUTH MEETING, Pa., Feb. 17, 2021 /PRNewswire/ The National Comprehensive Cancer Network
®) today published its first-ever treatment guidelines for children with a solid tumor cancer type in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
Medication reconciliation is a critical component of the oncology pharmacistʼs duties that has been performed safely over the phone with the patient, caregiver, and pharmacy with the assistance of electronic health records.
Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope s Genomics Institute, TGen
Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders
News provided by
Share this article
(PRNewsfoto/EXACT SCIENCES CORP)
(PRNewsfoto/EXACT SCIENCES CORP)
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has entered into an agreement to acquire Ashion Analytics, LLC (Ashion) from The Translational Genomics Research Institute (TGen), an affiliate of City of Hope. Ashion is a CLIA-certified and CAP-accredited sequencing lab based in Phoenix, Arizona with the genomics testing capabilities necessary to address the increasingly complex needs of clinical, academic, and biopharma customers focused on precision cancer treatments. The team at Ashion will help accelerate the development of Exact Sciences precision oncology portfolio, including
Unexpected Findings on Weight Loss and Breast Cancer from International Study in JNCCN
New research found that weight loss after diagnosis was associated with worse outcomes for HER2-positive early breast cancer patients
News provided by
Share this article
PLYMOUTH MEETING, Pa., Feb. 16, 2021 /PRNewswire/ New research in the February 2021 issue of
JNCCN Journal of the National Comprehensive Cancer Network examined body mass index (BMI) data for people with HER2-positive early breast cancer, and found a 5% weight loss in patients over two years in was associated with worse outcomes. Weight gain over the same time period did not affect survival rates.
Exact Sciences Announces Fourth Quarter 2020 Results
News provided by
Share this article
Share this article
MADISON, Wis., Feb. 16, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. Exact Sciences finished another transformative year by delivering strong fourth quarter results against a challenging backdrop because of the pandemic, said Kevin Conroy, chairman and CEO of Exact Sciences. We are a leader in cancer diagnostics because of our people, scientific platform, and market-leading Cologuard and Oncotype tests. We aim to extend this leadership throughout the cancer continuum and bring additional tests to patients to help improve cancer outcomes.